<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of cryoglobulins and cryoglobulinemia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of cryoglobulins and cryoglobulinemia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of cryoglobulins and cryoglobulinemia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrice Cacoub, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark H Wener, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Philip Seo, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 14, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Precipitation of blood proteins at temperatures lower than 37°C is referred to as cryoprecipitation. Two major types of cryoprecipitates are recognized. Cryoglobulin is present when proteins precipitate from an individual's serum and plasma, and cryofibrinogen refers to the precipitate from plasma only [
         <a href="#rid1">
          1
         </a>
         ]. Cryoglobulins are composed of either immunoglobulins (Igs) or a mixture of Igs and complement components.
        </p>
        <p>
         The diagnosis of a cryoglobulinemia syndrome should be suspected in patients presenting with arthralgia, purpura, skin ulcers, glomerulonephritis, and peripheral neuropathy. The index of suspicion for cryoglobulinemia should be raised further if these occur in the setting of a chronic viral hepatitis (especially hepatitis C virus [HCV]), a monoclonal gammopathy (eg, multiple myeloma; Waldenström macroglobulinemia; monoclonal gammopathy of undetermined significance [MGUS], which then turns to monoclonal gammopathy of clinical significance [MGCS]), monoclonal gammopathies of renal significance, or connective tissue disease (eg, systemic lupus erythematosus [SLE], Sjögren's disease).
        </p>
        <p>
         The nature of cryoglobulins, an overview of the clinical syndromes associated with them (cryoglobulinemia, cryoglobulinemic vasculitis), their pathogenesis, associated disorders, and prognosis are the subjects of this topic review. Treatment of cryoglobulinemia due to plasma cell disorders (monoclonal cryoglobulin) and the clinical manifestations, diagnosis, and treatment of the mixed cryoglobulinemia syndromes, such as those associated with hepatitis C infection, are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/6654.html" rel="external">
          "Treatment and prognosis of Waldenström macroglobulinemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3062.html" rel="external">
          "Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3070.html" rel="external">
          "Mixed cryoglobulinemia syndrome: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
         The clinical manifestations of cryofibrinogenemia and disorders associated with the presence of circulating cryofibrinogen are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1321.html" rel="external">
          "Disorders of fibrinogen", section on 'Cryofibrinogenemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1785302503">
         <span class="h1">
          TERMINOLOGY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cryoglobulin
         </strong>
         – Cryoglobulins are Igs in the serum that precipitate in vitro
         <em>
         </em>
         at temperatures below 37°C and redissolve on rewarming. The appearance of precipitated cryoglobulin is illustrated in the picture  (
         <a class="graphic graphic_picture graphicRef126400" href="/z/d/graphic/126400.html" rel="external">
          picture 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cryoglobulinemia
         </strong>
         – Cryoglobulinemia refers to the presence of cryoglobulin in a patient's serum. This term is sometimes used interchangeably with cryoglobulinemic vasculitis (or cryoglobulinemia syndrome).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cryoglobulinemic vasculitis
         </strong>
         – Cryoglobulinemic vasculitis (or cryoglobulinemia syndrome) refers to a systemic inflammatory syndrome that generally involves small-to-medium vessel vasculitis due to cryoglobulin-containing immune complexes. This term is generally used to distinguish the asymptomatic presence of cryoglobulins from the clinically apparent disorder with end-organ damage caused by cryoglobulins precipitating in small- to medium-sized blood vessels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mixed cryoglobulinemia
         </strong>
         – Mixed cryoglobulinemia refers to cryoglobulins that contain more than one immunoglobulin component (for example, IgM rheumatoid factor [RF] and polyclonal IgG). Mixed cryoglobulinemia may be primary or idiopathic cryoglobulinemia, as well as cryoglobulinemia associated with autoimmune diseases, malignancy, or infection. Type II and III mixed cryoglobulinemias correspond to either a monoclonal Ig with polyclonal Igs or polyclonal Igs, respectively. The distinction of these subtypes is meaningful because underlying diseases vary according to each subtype. Mixed cryoglobulinemia syndrome can be caused by either type II or III cryoglobulins, the characteristics of which are described below. (See
         <a class="medical medical_review" href="/z/d/html/3062.html" rel="external">
          "Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="local">
          'Mixed cryoglobulinemia (types II/III)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Essential mixed cryoglobulinemia
         </strong>
         – Essential mixed cryoglobulinemia was the traditional term for what was thought to be idiopathic vasculitis caused by circulating cryoglobulins that contain both a polyclonal IgG and an IgM RF directed against the IgG, which are called mixed cryoglobulins. It was later discovered that in most patients, this disorder is associated with chronic hepatitis C virus (HCV) infection. Therefore, this term currently refers to the very small percentage of patients with mixed cryoglobulinemic vasculitis in the absence of underlying disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hyperviscosity
         </strong>
         <strong>
          syndrome
         </strong>
         – Hyperviscosity syndrome may be present with cryoglobulinemia due to hematologic malignancies and monoclonal Igs (mainly type I cryoglobulinemia). (See
         <a class="medical medical_review" href="/z/d/html/6657.html" rel="external">
          "Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia", section on 'Hyperviscosity syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Meltzer's triad
         </strong>
         – Meltzer's triad refers to the clinical triad of palpable purpura, arthralgia, and weakness. It is generally seen with the mixed cryoglobulinemia syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immune complex
         </strong>
         – The multimolecular combination of antibodies bound to their target antigens are referred to as immune complexes. They may be present in blood as circulating immune complexes or present in tissues and organs.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1164979115">
         <span class="h1">
          CLASSIFICATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Brouet classification criteria is the most commonly used system that classifies cryoglobulinemia into three different subgroups based on their Ig composition [
         <a href="#rid2">
          2
         </a>
         ]. These classification criteria are also useful in that the subgroups partly correlate with pathogenicity and clinical manifestations.
        </p>
        <p class="headingAnchor" id="H1936245079">
         <span class="h2">
          Type I
         </span>
         <span class="headingEndMark">
          —
         </span>
         In type I cryoglobulinemia, the cryoglobulins are monoclonal Igs, typically IgG or IgM, and less commonly IgA or free Ig light chains. Type I cryoglobulinemia develops in the setting of protein-secreting monoclonal gammopathies such as a monoclonal gammopathy of undetermined significance (MGUS), which then turns to monoclonal gammopathy of clinical significance (MGCS) or a B-cell lineage malignancy (eg, multiple myeloma, Waldenström macroglobulinemia, or chronic lymphocytic leukemia). (See
         <a class="medical medical_review" href="/z/d/html/6657.html" rel="external">
          "Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">
          "Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
         Type II and III cryoglobulins are mixed cryoglobulins, meaning that, unlike type I cryoglobulins, their constituent Ig is not a single monoclonal Ig.
        </p>
        <p class="headingAnchor" id="H2918354099">
         <span class="h2">
          Type II
         </span>
         <span class="headingEndMark">
          —
         </span>
         In type II cryoglobulinemia, the cryoglobulins are composed of a mixture of a monoclonal IgM (or IgG or IgA) with rheumatoid factor (RF) activity and polyclonal Ig. Type II cryoglobulins are often associated with persistent viral infections, particularly hepatitis C virus (HCV) infection, and are associated with the mixed cryoglobulinemia syndrome [
         <a href="#rid3">
          3
         </a>
         ]. Other clinical associations with type II cryoglobulinemia include autoimmune diseases (mainly systemic lupus erythematosus [SLE] and Sjögren's disease), lymphoproliferative disorders, and less frequently other infections such as hepatitis B virus (HBV) and human immunodeficiency virus (HIV). In approximately 10 percent of cases, there is no identifiable disease association and the cryoglobulinemia is called "essential." (See
         <a class="medical medical_review" href="/z/d/html/3062.html" rel="external">
          "Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3105760392">
         <span class="h2">
          Type III
         </span>
         <span class="headingEndMark">
          —
         </span>
         In type III cryoglobulinemia, the cryoglobulins are composed of a mixture of polyclonal IgG (all isotypes) and polyclonal IgM. These cases are often secondary to autoimmune disorders, but can also be associated with infections (mainly HCV).
        </p>
        <p>
         While generally useful, this schema does not account for cryoglobulins that possess atypical characteristics, such as oligoclonal IgM components with or without trace polyclonal Ig responses, often referred to as type II-III [
         <a href="#rid4">
          4,5
         </a>
         ] or biclonal cryoglobulins [
         <a href="#rid6">
          6,7
         </a>
         ]. Many speculate that such phenomena reflect an intermediate stage of transition between type II and III, akin to the malignant transformation of MGUS to multiple myeloma or other lymphoproliferative disorders [
         <a href="#rid8">
          8
         </a>
         ], but a direct pathogenic link has not been clearly demonstrated. (See
         <a class="medical medical_review" href="/z/d/html/15772.html" rel="external">
          "Clinical course and management of monoclonal gammopathy of undetermined significance"
         </a>
         .)
        </p>
        <p>
         In addition to classification by the Ig constituents of the cryoglobulin, cryoglobulinemia syndromes are often classified as idiopathic or secondary, based upon the presence of underlying diseases, particularly chronic HCV infection or connective tissue diseases [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         At the same time, the clinical features of both idiopathic and secondary mixed cryoglobulinemia overlap somewhat, with respect to Brouet subtype and organ involvement, making most distinctions among cryoglobulin syndromes somewhat difficult to interpret consistently.
        </p>
        <p class="headingAnchor" id="H2935854104">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of clinically significant cryoglobulinemia has been estimated at approximately 1 in 100,000. However, detectable levels of circulating cryoglobulins, without clinical manifestations of vasculitis, have been seen in a significant proportion of patients with chronic infections and/or inflammation: 15 to 20 percent in HIV infection, 15 to 25 percent in connective tissue diseases, 40 to 65 percent in hepatitis C-infected individuals, and as high as 64 percent in HIV and hepatitis C coinfection [
         <a href="#rid10">
          10-14
         </a>
         ]. The proportion of patients with a type I cryoglobulin varies substantially among case series but accounts for approximately 5 to 25 percent of cases.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          ETIOPATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Since minute levels of cryoglobulin may be detectable in the serum of healthy persons, many researchers have speculated that they reflect the ongoing presence of endogenous immune complexes to be cleared from the circulation by Igs with rheumatoid factor (RF) activity [
         <a href="#rid2">
          2,15
         </a>
         ]. In such a scenario, pathogenic cryoglobulin responses would result from several factors, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic immune stimulation and/or lymphoproliferation, resulting in the production of higher concentrations of mono-, oligo-, or polyclonal immunoglobulins that can form cryoglobulins
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Enhanced immune complex (antigen-antibody complex) formation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Defective and/or insufficient clearance of the resulting immune complexes, which accumulate and mediate disease
        </p>
        <p>
        </p>
        <p>
         Cryoglobulin pathogenesis may depend upon a poorly understood interaction between a polygenic host predisposition and environmental triggers. Major histocompatibility complex (MHC) associations, for instance, have been extensively investigated in hepatitis C virus (HCV)-associated mixed cryoglobulinemia [
         <a href="#rid16">
          16
         </a>
         ]. A genome-wide significant association with cryoglobulin-related vasculitis was identified with single nucleotide polymorphisms (SNPs) near
         <em>
          NOTCH4
         </em>
         and
         <em>
          MHC
         </em>
         class II genes [
         <a href="#rid17">
          17
         </a>
         ]. Significantly elevated levels of inflammatory cytokines, such as interleukin (IL)-1-beta, IL-6, and tumor necrosis factor (TNF)-alpha, have been observed, suggesting a particular role for cryoglobulin-induced inflammation in disease pathogenesis [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         Although HIV and HCV coinfection are relatively common, the combination of the two viral agents appears to have variable effect upon the prevalence of cryoglobulin or symptomatic cryoglobulinemia syndromes [
         <a href="#rid19">
          19
         </a>
         ]. Other infectious agents proven to have an association with cryoglobulinemia include hepatitis B, cytomegalovirus, Epstein-Barr virus, and human parvovirus B19 [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Type I cryoglobulins
         </strong>
         – Type I cryoglobulinemia causes hyperviscosity that results from high levels of monoclonal cryoglobulins due to an underlying lymphoproliferative disorder. These Igs form cold-induced precipitates that induce a microthrombotic process within small size vessels. In vivo, such aggregates may physically obstruct vessels and rarely mediate inflammatory vasculitis via immune complex deposition [
         <a href="#rid21">
          21
         </a>
         ], as suggested by studies of human cryoglobulins in animal models [
         <a href="#rid22">
          22
         </a>
         ]. For many cryoglobulins, aggregation and pathogenicity appear to depend upon antibody-specific conditions of temperature, pH, Ig concentration, and weak noncovalent factors [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Types II and III cryoglobulins
         </strong>
         – The mixed cryoglobulins (types II and III) generally result in two-thirds of cases from connective tissue diseases, such as systemic lupus erythematosus (SLE) or, more rarely, Sjögren's disease [
         <a href="#rid24">
          24
         </a>
         ], whereas in one-third, they are associated with chronic HCV infection [
         <a href="#rid25">
          25
         </a>
         ]; other viral infections, such as hepatitis B virus (HBV) or HIV; and lymphoproliferative disorders. Many of these disease states share B-cell hyperactivation and/or hyperproliferation [
         <a href="#rid14">
          14,26
         </a>
         ], which seem to predispose to the selective expansion of cryoglobulin-producing B-cell clone(s) [
         <a href="#rid27">
          27
         </a>
         ], but a precise ontology of pathogenic cryoglobulins in mixed cryoglobulinemia has not been delineated. This paradigm of pathogenesis has been most intensively studied for chronic HCV infection, in which B-cell hyperactivation may result upon direct infection via the cell surface protein CD81 [
         <a href="#rid28">
          28
         </a>
         ]; via chronic, antigen-nonspecific stimulation by macromolecular serum complexes containing HCV, including HCV-IgG and HCV-lipoprotein [
         <a href="#rid29">
          29,30
         </a>
         ]; or via an HCV antigen-specific mechanism [
         <a href="#rid31">
          31
         </a>
         ], resulting in expansion of specific B-cell clones [
         <a href="#rid32">
          32,33
         </a>
         ]. HCV particles are often found in such patients' serum cryoglobulin complexes, but, at the same time, cryoglobulin development in hepatitis C infection does not directly require the HCV virion or its components [
         <a href="#rid34">
          34
         </a>
         ]. In this sense, cryoglobulin development may, in fact, reflect a normal, expected response to regulate immune complexes in states of chronic immune activation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Among patients with HCV infection, the number of circulating T cells with surface markers compatible with a suppressor phenotype is a feature that differs between patients with cryoglobulinemic vasculitis and those with asymptomatic cryoglobulinemia. This was illustrated in a study that compared the percentage of regulatory T cells in 69 patients with HCV infection who had symptomatic cryoglobulinemia with others with asymptomatic HCV infection [
         <a href="#rid35">
          35
         </a>
         ]. The mean levels of regulatory T cells were significantly lower in those with symptomatic HCV-associated cryoglobulinemia than asymptomatic subjects (2.6 versus 7.4 percent, respectively). Two clinical trials confirm the major role of regulatory T cells in HCV-associated cryoglobulinemia, showing a significant increase of these cells after antivirals or low-dose IL-2 correlates with less clinical activity of the vasculitis [
         <a href="#rid36">
          36,37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aggregation
         </strong>
         – The molecular characteristics of cryoglobulins similarly vary depending upon the underlying disease state. Most commonly, type II cryoglobulins contain germline autoantibodies with RF activity, suggesting an antigen-independent, hyperproliferative etiology [
         <a href="#rid29">
          29,38
         </a>
         ]. Nevertheless, non-RF cryoglobulins have been described, mostly in type I cryoglobulinemia, in which cryoprecipitability seems to be mediated by other characteristics of the Ig molecule itself, such as the absence of sialic acid moieties [
         <a href="#rid39">
          39
         </a>
         ]. Furthermore, specific factors may be required within the IgG and/or target antigen(s) of the cryoglobulin, especially in the mixed cryoglobulinemias, since many cryoprecipitates form best between the cryoglobulin in association with the respective patient's IgG and/or its Fc, but not with IgG from normal serum [
         <a href="#rid40">
          40
         </a>
         ]. These findings suggest that cryoglobulins result from the specific selection of antibodies with such characteristics by the pathologic processes responsible for cryoglobulin development, rather than emerging from a random, stochastic process.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Classically, the overproduction of cryoglobulins and the resulting aggregates and/or circulating immune complexes are thought to overwhelm normal mononuclear phagocyte system activity, perhaps by impairing normal Fc receptor function, leading to the accumulation of serum cryoglobulin complexes that deposit in target tissues where they induce disease [
         <a href="#rid41">
          41,42
         </a>
         ]. Indeed, some familial forms of cryoglobulinemia have been associated with deficiencies in complement proteins [
         <a href="#rid43">
          43,44
         </a>
         ] and presumably result from the inability of these patients to effectively clear cryoglobulin-containing immune complexes.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          OVERVIEW OF CLINICAL PRESENTATION AND DISEASE ASSOCIATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical presentations of cryoglobulin syndromes vary substantially among series, probably due in large part to both differences of case definition and prevalence of secondary etiologies [
         <a href="#rid3">
          3
         </a>
         ]. The majority of people with cryoglobulins are asymptomatic. When a clinically significant disorder is associated with the presence of cryoglobulins, the symptoms and physical findings are generally correlated with the underlying Brouet type of cryoglobulin. (See
         <a class="local">
          'Classification'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Type I cryoglobulinemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Type I cryoglobulinemia classically produces symptoms and signs related to vascular occlusion by the cryoprecipitate such as digital ischemia, livedo reticularis, and skin necrosis [
         <a href="#rid45">
          45-48
         </a>
         ]. Such manifestations are frequently dependent on a low outside temperature. Skin manifestations are most commonly observed in these patients, with reports of up to 70 to 85 percent. Raynaud phenomenon is also frequent, and in severe cases, without treatment of the underlying disease, may progress to digital gangrene. Estimates for the frequency of extracutaneous disease includes peripheral neuropathy in approximately 20 to 45 percent of patients, arthralgia in 30 percent, and renal disease in 30 percent. When the cryocrit is high, symptoms of hyperviscosity may occur that include blurring or loss of vision, headache, vertigo, nystagmus, dizziness, sudden deafness, diplopia, ataxia, confusion, dementia, disturbances of consciousness, stroke, or coma.
        </p>
        <p>
         A nationwide retrospective study in France identified 64 patients with symptomatic type I cryoglobulins over a 15-year period [
         <a href="#rid45">
          45
         </a>
         ]. All patients had either a hematologic malignancy (56 percent, most often Waldenström macroglobulinemia or multiple myeloma) or a monoclonal gammopathy of undetermined significance (MGUS; 44 percent). Cutaneous involvement, sometimes severe and resulting in ulcerations and necrosis, was often present; other common findings included peripheral neuropathy, as well as arthralgia or arthritis. Renal disease (usually a membranoproliferative glomerulonephritis) was seen in 30 percent of the affected patients. None of the patients exhibited central nervous system, pulmonary, cardiac, or gastrointestinal manifestations. Treatment for these symptoms included glucocorticoids, plasma exchange, alkylating agents,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , and other chemotherapy; 10 percent of the patients did not require treatment. Ten-year survival was 87 percent, with relatively poorer survival rates in the patients with hematologic malignancy. Another report of a series of patients with symptomatic type I cryoglobulinemia showed that IgG cryoglobulins were mainly associated with MGUS and multiple myeloma, whereas IgM cryoglobulins were associated with MGUS and Waldenström macroglobulinemia [
         <a href="#rid46">
          46
         </a>
         ]. These different cryoglobulin isotypes should have an impact on the choice of treatment as the target cell will be the B lymphocyte or the plasmocyte, respectively. The prognosis of type I cryoglobulinemia has largely reflected the usual underlying lymphoproliferative disorder, such as Waldenström macroglobulinemia or multiple myeloma. (See
         <a class="medical medical_review" href="/z/d/html/6657.html" rel="external">
          "Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia", section on 'Hyperviscosity syndrome'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">
          "Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Mixed cryoglobulinemia (types II/III)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mixed cryoglobulinemia is most often associated with constitutional and nonspecific symptoms, such as arthralgias, fatigue, and myalgias, as well as palpable purpura due to cutaneous vasculitis and sensory changes or weakness due to peripheral neuropathy [
         <a href="#rid49">
          49
         </a>
         ]. The classical "Meltzer's triad" of purpura, arthralgias, and weakness is seen in most patients [
         <a href="#rid9">
          9,50
         </a>
         ]. Purpura is the most common manifestation, usually involving the legs, but it can extend to the torso and upper extremities [
         <a href="#rid47">
          47
         </a>
         ]. A membranoproliferative glomerulonephritis is seen in 20 to 30 percent of the affected patients. Manifestations often wax and wane over time, with spontaneous remissions and exacerbations [
         <a href="#rid51">
          51
         </a>
         ]. Symptoms often last one to two weeks, recurring one to two times per month, but, in severe cases, discrete exacerbations may be difficult to discern.
        </p>
        <p class="headingAnchor" id="H3355821425">
         <span class="h1">
          SPECIFIC CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Cutaneous involvement and vasomotor symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cutaneous manifestations develop in nearly all patients with cryoglobulin syndromes [
         <a href="#rid2">
          2,9,52-54
         </a>
         ] and may precede extracutaneous manifestations by decades. Typically, these lesions consist of erythematous macules and purpuric papules of the lower extremities (90 to 95 percent)  (
         <a class="graphic graphic_picture graphicRef51770" href="/z/d/graphic/51770.html" rel="external">
          picture 2
         </a>
         ), though infarction, hemorrhagic crusts, and ulcers also occur (10 to 25 percent), generally in patients with type I cryoglobulinemia. Similarly, Raynaud phenomenon, livedo reticularis, and acrocyanosis more commonly manifest in type I cryoglobulinemia as mentioned above (see
         <a class="local">
          'Mixed cryoglobulinemia (types II/III)'
         </a>
         above). Postinflammatory hyperpigmentation (30 to 50 percent) and exacerbation as a result of cold exposure (10 to 30 percent) are common. Morphologic abnormalities of the nailfold vasculature, including tortuosity and apical enlargement, are seen on capillaroscopy [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Musculoskeletal involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Musculoskeletal complaints such as arthralgias and myalgias are common in the mixed cryoglobulinemias, but frank arthritis or myositis is rare [
         <a href="#rid16">
          16,56
         </a>
         ]. Arthralgias are typically described in over 70 percent of patients, especially affecting the metacarpophalangeal and proximal phalangeal joints, knees, and ankles, often in type III cryoglobulinemia. They rarely accompany type I cryoglobulinemia.
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Peripheral nerve involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neuropathy affects a high percentage of patients with mixed, in contrast to type I, cryoglobulinemia. Electromyographic and nerve conduction studies have demonstrated the presence of peripheral neuropathy in over 70 to 80 percent of patients with mixed cryoglobulins [
         <a href="#rid15">
          15,57-59
         </a>
         ], but many symptom-based demographic studies report prevalences of only 30 to 45 percent. Severe peripheral neuropathy, such as mononeuropathy multiplex or combined sensorimotor disease, is uncommon [
         <a href="#rid60">
          60-62
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8236.html" rel="external">
          "Clinical manifestations and diagnosis of vasculitic neuropathies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Renal involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Renal disease in mixed cryoglobulinemia often results from immune complex disease or, less often, as a result of thrombotic disease (the latter is more often seen in type I disease) [
         <a href="#rid2">
          2,63
         </a>
         ]. Cryoglobulinemia was the cause of biopsy-proven glomerulonephritis in approximately 2 percent of cases in an Italian registry of renal biopsies [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
         Membranoproliferative glomerulonephritis is more common in mixed cryoglobulinemia, and variations in underlying etiology likely account for the wide variation in the reported incidence of renal disease among various case series (5 to 60 percent). Isolated proteinuria or hematuria occurs much more frequently than nephrotic or nephritic syndromes or acute renal failure [
         <a href="#rid65">
          65,66
         </a>
         ]. Most patients declare chronic or rapidly progressive disease course within three to five years of diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/3062.html" rel="external">
          "Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3350815062">
         <span class="h2">
          Pulmonary involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Subclinical pulmonary manifestations appear to be common in mixed, but not type I, cryoglobulinemia [
         <a href="#rid67">
          67-69
         </a>
         ]. Pulmonary function tests often reveal evidence of small airways disease and impairment of gas exchange, with symptoms in approximately 10 to 20 percent of patients, usually ranging from dyspnea to cough and pleurisy. Organizing pneumonia, alveolar hemorrhage, and pulmonary vasculitis have been reported but appear to be very uncommon.
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Other organ involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other manifestations have been reported with varying frequency, such as lymphadenopathy in up to 20 percent; splenomegaly in up to 30 percent; and abdominal pain in up to 20 percent (which sometimes reflects active mesenteric vasculitis) [
         <a href="#rid15">
          15,70
         </a>
         ]. Other manifestations such as hepatomegaly, abnormal liver function tests, or abnormal liver biopsy in up to 90 percent are not related to the cryoglobulinemia itself but to the main cause (eg, hepatitis C virus [HCV] infection). Clinically significant vasculitis of most other internal organs, such as of the heart, central nervous system, and retinal vessels, rarely complicates any of the cryoglobulinemia syndromes, with the possible exception of those with hyperviscosity due to type I cryoglobulinemia. However, pathologic findings suggest that more widespread, though subclinical, involvement may be more frequent. (See
         <a class="local">
          'Biopsy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h1">
          DIAGNOSTIC APPROACH
         </span>
        </p>
        <p class="headingAnchor" id="H3921271767">
         <span class="h2">
          When to suspect the diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The range of clinical presentations associated with the various cryoglobulinemia syndromes is broad, but some of the more common features include arthralgia, purpura, skin ulcers, glomerulonephritis, and peripheral neuropathy. The index of suspicion for cryoglobulinemia should be raised further if these occur in the setting of a clonal hematologic disease (eg, multiple myeloma, Waldenström macroglobulinemia), viral infection (eg, hepatitis C virus [HCV], hepatitis B virus [HBV]), or connective tissue disease (eg, systemic lupus erythematosus [SLE], Sjögren's disease, or rheumatoid arthritis).
        </p>
        <p>
         Overall, the presence of a measurable amount of cryoglobulin (cryocrit) with a low C4 complement level remain the most prominent laboratory hallmarks of cryoglobulinemia syndromes [
         <a href="#rid52">
          52
         </a>
         ]. Several other serologic findings have often been reported, but none are pathognomonic since they are often encountered in healthy individuals and/or other confounding medical conditions.
        </p>
        <p class="headingAnchor" id="H1802105384">
         <span class="h2">
          Evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial evaluation for patients with suspected cryoglobulinemic vasculitis should include an assessment for associated diseases as well as other possible comorbidities.
        </p>
        <p class="headingAnchor" id="H937949087">
         <span class="h3">
          History and physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some of the key elements of the history include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior or concomitant history of a clonal hematologic disease (eg, multiple myeloma, Waldenström macroglobulinemia, monoclonal gammopathy of undetermined significance [MGUS])
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Concomitant autoimmune diseases such as SLE or Sjögren's disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Concomitant infection with HBV, HCV, or HIV
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Past or current skin purpura of the lower limbs
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Skin ulcers or thromboses when exposed to cold outside temperature
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute foot or wrist drop suggestive of a motor neuropathy from an ischemic process
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Constitutional symptoms and nonspecific symptoms such as fever, fatigue, weight loss, arthralgias, and myalgias
        </p>
        <p>
        </p>
        <p>
         A careful physical examination helps identify potential sites of vasculitis and determine the extent of vascular lesions, the distribution of affected organs, and the presence of additional disease processes. Certain findings, such as diminished sensation to touch and motor weakness of the extremities due to neuropathic changes consistent with mononeuritis multiplex and palpable purpura, are highly suggestive of an underlying vasculitic process. A skin exam may reveal purpura, livedo reticularis, skin necrosis, or ulcers.
        </p>
        <p class="headingAnchor" id="H874889765">
         <span class="h3">
          Laboratory evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to detection of cryoglobulins, laboratory testing for all patients with suspected cryoglobulinemia should include additional testing to assess the degree of organ involvement as well as determine the presence of associated diseases.
        </p>
        <p class="headingAnchor" id="H2245825540">
         <span class="h4">
          Detection of cryoglobulins
         </span>
         <span class="headingEndMark">
          —
         </span>
         To detect cryoglobulin, 10 to 20 mL of blood are drawn into syringes and/or collection tubes that have been
         <strong>
          prewarmed to 37ºC without anticoagulants
         </strong>
         . These precautions are required because failure to prewarm may lead to false-negative results, due to loss of the cryoglobulin in the clotted blood (eg, if there is cooling below 37°C during collection, clotting, or centrifugation) and because the presence of anticoagulants may produce false-positive results due to the formation of cryofibrinogen or heparin-precipitable complexes.
        </p>
        <p>
         After clotting at 37°C for one-half to one hour, the serum is separated by centrifugation at 37°C, placed in a graduated (Wintrobe) tube, and refrigerated (4°C) to allow the precipitation of cryoglobulin. In type I cryoglobulinemia, precipitates are often seen within 24 hours (sometimes in less than 90 minutes). However, three to five days are usually allowed for complete precipitation, especially for the mixed cryoglobulins, and some type II and type III cryoglobulins require up to seven days for precipitation  (
         <a class="graphic graphic_picture graphicRef126400" href="/z/d/graphic/126400.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid71">
          71
         </a>
         ]. Most laboratories will determine a cryocrit, which is a measure of the packed (centrifuged) volume of the precipitate as a percentage of the original serum volume at 4°C.
        </p>
        <p>
         Further confidence that the precipitate is a true cryoglobulin is obtained by washing the precipitate three to six times in cold
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         solution to reduce the possibility of precipitated salts or other proteins. In addition, the precipitate can then be redissolved in saline at 37°C to confirm the warm solubility of the cryoglobulins. At this time, cryoglobulin protein concentration can be determined by spectrophotometry. Further characterization can be accomplished by immunofixation, enzyme-linked immunosorbent assay (ELISA), or another specific immunologic assay.
        </p>
        <p>
         Some laboratories perform further testing consisting of a measurement of absolute cryoglobulin concentration, along with a description of the components of the immune complexes, including mono- or polyclonality of IgM, IgG, IgA, IgE, kappa, and/or lambda light chains. In type II cryoglobulinemia, the monoclonal component is typically IgM kappa with rheumatoid factor (RF) activity.
        </p>
        <p>
         The cryocrit in individuals without cryoglobulinemia is close to zero; generally, a cryocrit over 0.5 to 1 percent or cryoglobulin concentration over 50 mcg/L is considered clinically significant [
         <a href="#rid52">
          52,72,73
         </a>
         ]. The cryocrit in affected patients may approach 50 percent or may encompass the entire serum volume in type I cryoglobulinemia under conditions in which the monoclonal protein forms a gel.
        </p>
        <p>
         The cryocrit is generally between 2 and 7 percent in type II and between 1 and 3 percent in type III disease, but there is a poor correlation between the cryocrit and clinical symptoms and features [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
         When cryoglobulinemia is suspected clinically, a negative result from routine laboratory testing for cryoglobulins does not exclude cryoglobulin-mediated disease [
         <a href="#rid75">
          75
         </a>
         ]. The clinician may need to draw a new specimen after consulting with the laboratory staff or clinical pathologist to assure that procedures are in place for the appropriate handling of the patient's blood when the sample is obtained and transported and to be certain that the laboratory has the necessary equipment (particularly a temperature-controlled centrifuge) to prevent premature cooling of the sample.
        </p>
        <p class="headingAnchor" id="H3844405929">
         <span class="h4">
          Immunochemical analysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         After the detection of cryoglobulinemia, it is categorized by immunochemical analysis into three different types. In order to analyze the nature of the cryoglobulin, it must be redissolved by warming and subjected to laboratory testing to determine its Ig and complement components [
         <a href="#rid4">
          4
         </a>
         ]. This is accomplished by performing immunofixation of the redissolved cryoglobulin by antibodies directed to various Ig heavy chains (IgG, IgM, etc) and light chains (eg, kappa and lambda) and to complement components (eg, C1q, C4, and C3) or similar immunologic analyses. (See
         <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">
          "Laboratory methods for analyzing monoclonal proteins"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1255870750">
         <span class="h4">
          Additional laboratory testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory testing for all patients with suspected cryoglobulinemia should include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serum chemistries and a urinalysis
         </strong>
         – A serum creatinine and urinalysis may help identify the presence of kidney involvement and the degree of injury if present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complement
         </strong>
         – Diminished serum complement components may reflect ongoing consumption by cryoglobulin-containing or cryoglobulin-propagated immune complexes [
         <a href="#rid9">
          9,76
         </a>
         ]. Type I cryoglobulins typically produce few serologic complement abnormalities. Mixed cryoglobulinemia sera often demonstrate reduced levels of total hemolytic complement (CH50) and early complement proteins C1q, C2, and C4, particularly in type II cryoglobulinemia. Rarely, monoclonal immunoglobulin may also cause C3 glomerulopathy or atypical hemolytic uremic syndrome by interfering with the regulation of the alternative pathway of complement. Of note, in mixed cryoglobulinemia, low levels of C4 are a major marker of disease activity. Levels of C3 are generally unaffected or only mildly diminished [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rheumatoid factor
         </strong>
         – RF is usually present, often at high levels, in sera of patients with type II mixed cryoglobulinemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Viral serologies
         </strong>
         – Serologic studies, particularly for viral hepatitis, are always indicated during the laboratory evaluation of a patient with mixed cryoglobulinemia. Hepatitis C has been reported in 60 to 90 percent of patients with mixed cryoglobulinemia syndromes, but other populations may have lower rates [
         <a href="#rid29">
          29,78
         </a>
         ]. Serologic studies for other agents, including hepatitis B, HIV, and Epstein-Barr virus, have been somewhat inconsistent but are generally worth at least considering during the workup of cryoglobulinemia [
         <a href="#rid79">
          79,80
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute phase reactants
         </strong>
         – Other tests appear to reflect a chronic inflammatory response. Acute phase reactants such as the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are generally elevated, and the ESR can be strikingly so in type I cryoglobulinemia, reflective of the underlying monoclonal Ig. Mild to moderate hypergammaglobulinemia of IgM, IgA, and/or IgG also typifies mixed cryoglobulinemia, with extremely elevated levels more indicative of type I cryoglobulinemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other autoantibodies
         </strong>
         – Other autoantibodies that should be included as part of the initial evaluation for a patient with suspected cryoglobulinemia include an antinuclear antibody (ANA) test, as well as testing for other specific antibodies such as double-stranded deoxyribonucleic acid (dsDNA), anti-Sm, Ro/SSA, La/SSB, and U1 ribonucleoprotein (RNP) [
         <a href="#rid3">
          3,9
         </a>
         ]. False-positive test results for antibodies to citrullinated peptide antigens (ACPA) in a small proportion of patients with hepatitis C-related cryoglobulinemia (7 percent) have been ascribed to nonspecific binding of Ig in the assay [
         <a href="#rid81">
          81
         </a>
         ]. Antineutrophil cytoplasmic antibody (ANCA) should be included as part of the workup to distinguish cryoglobulinemic vasculitis from the possible ANCA-associated vasculitides. (See
         <a class="medical medical_review" href="/z/d/html/7503.html" rel="external">
          "Biologic markers in the assessment of rheumatoid arthritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2543399277">
         <span class="h3">
          Specific testing in selected patients
         </span>
        </p>
        <p class="headingAnchor" id="H4247191326">
         <span class="h4">
          Biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although often not required for diagnostic purposes, biopsies of affected organs can help provide histopathologic evidence of cryoglobulinemic vasculitis. Type I cryoglobulinemia (monoclonal Ig-containing) predominantly affects the skin, kidney, and bone marrow; the main pathologic features are related to thromboses. Mixed cryoglobulinemia syndromes (types II and III) predominantly involve the skin, kidney, and peripheral nervous system; the main features are related to immune complex vasculitis. The histopathologic findings on biopsies of affected organs are described below.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Skin
         </strong>
         – Skin lesions in mixed cryoglobulinemia most often reveal leukocytoclastic vasculitis (50 percent), less commonly inflammatory or noninflammatory purpura (10 to 20 percent)  (
         <a class="graphic graphic_picture graphicRef54126" href="/z/d/graphic/54126.html" rel="external">
          picture 3
         </a>
         ), noninflammatory hyaline thrombosis (10 percent), or postinflammatory sequelae (10 percent). Direct immunofluorescence microscopy of acute lesions often reveals deposits of IgM, IgG, and/or C3 complement.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         By contrast, type I cryoglobulins more often induce noninflammatory thrombotic lesions, sometimes with evidence of cutaneous infarction or hemorrhage [
         <a href="#rid2">
          2,52,82
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Peripheral nerve
         </strong>
         – Peripheral nerve lesions typically demonstrate vasculitis, generally of the epineurial vessels, in mixed cryoglobulinemia [
         <a href="#rid60">
          60,83-87
         </a>
         ]. Necrotizing vasculitis or demyelination may be present, with occasional deposits of Ig and/or complement [
         <a href="#rid88">
          88
         </a>
         ]. Pauci-inflammatory occlusive lesions are sometimes seen as well, suggesting a primary role for neuronal ischemia in disease pathogenesis, and are more suggestive of type I cryoglobulinemia. Affected nerves often display axonal degeneration, likely secondary to disease of the vasa vasorum. Most studies have focused upon histopathology of sural nerve biopsies, which are presumed to reflect systemic neuronal damage.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kidney
         </strong>
         – On light and immunofluorescence microscopy, membranoproliferative pattern of injury of glomerulonephritis is most commonly observed (in 60 to 80 percent), with endocapillary proliferation and subendothelial and/or intraluminal deposits of cryoglobulins, Igs, and/or complement proteins  (
         <a class="graphic graphic_picture graphicRef71702" href="/z/d/graphic/71702.html" rel="external">
          picture 4
         </a>
         and
         <a class="graphic graphic_picture graphicRef60046" href="/z/d/graphic/60046.html" rel="external">
          picture 5
         </a>
         ) [
         <a href="#rid65">
          65,89
         </a>
         ]. Less commonly seen, but not mutually exclusive, are mesangial proliferative glomerulonephropathy, intraglomerular hyaline thrombi, and vasculitis with fibrinoid necrosis (approximately 20, 25, and 30 percent, respectively) [
         <a href="#rid15">
          15,90,91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Type I cryoglobulinemia generally produces noninflammatory glomerulopathies, including thrombotic and hypocellular lesions, without evidence of vasculitis. However, type I cryoglobulins may rarely produce frank glomerulonephritis, as was documented in two cases of membranoproliferative disease, both involving IgG monoclonal cryoglobulins of the same isotype [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When renal biopsy specimens are examined with electron microscopy, amorphous or granular dense subendothelial deposits may be present  (
         <a class="graphic graphic_picture graphicRef69200" href="/z/d/graphic/69200.html" rel="external">
          picture 6
         </a>
         ). The presence of electron-dense deposits that have a "fingerprint"-like appearance  (
         <a class="graphic graphic_picture graphicRef81450" href="/z/d/graphic/81450.html" rel="external">
          picture 7
         </a>
         ) may provide a clue to the presence of cryoglobulins [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone marrow
         </strong>
         – In type I cryoglobulinemia, bone marrow examination often reveals evidence of an underlying hematologic condition, such as plasma cell malignancy in multiple myeloma. Few studies have systematically explored bone marrow findings in mixed cryoglobulinemia, but monomorphic clusters of small lymphocytes, often with plasmacytoid features and associated with overexpression of the B-cell lymphoma 2 proto-oncogene, have been described [
         <a href="#rid94">
          94,95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3937457984">
         <span class="h4">
          Electromyography
         </span>
         <span class="headingEndMark">
          —
         </span>
         Electromyography (EMG) may be useful if symptoms of neuromuscular disease are present, such as findings of multiple mononeuropathy (also called mononeuritis multiplex). (See
         <a class="medical medical_review" href="/z/d/html/5145.html" rel="external">
          "Overview of electromyography"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2565514445">
         <span class="h4">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Imaging studies should be guided by the clinical presentation. An example of such a study would include a computed tomography (CT) scan of the chest, abdomen, and pelvis when searching for a lymphoproliferative disorder.
        </p>
        <p class="headingAnchor" id="H39">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnosis of a clinical disorder in association with cryoglobulinemia requires a careful consideration of combined clinical, laboratory, and pathologic data. Few investigators have adhered to any of the several proposed classification criteria for the cryoglobulinemia syndrome [
         <a href="#rid96">
          96,97
         </a>
         ]. While there are no established diagnostic criteria, we generally diagnose cryoglobulinemia as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Demonstration of an elevated cryocrit, such as greater than 1 percent or greater than 50 mcg/L.
        </p>
        <p>
        </p>
        <p>
         Plus one or more of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical indicators of cryoglobulinemic vasculitis or thrombosis with skin, joint, renal, peripheral nerve, central neurologic, gastrointestinal, pulmonary, and/or cardiac involvement
         <strong>
          and
         </strong>
         diminished serum C4 concentration (notably in mixed cryoglobulinemia syndromes). Histologic confirmation of leukocytoclastic vasculitis on skin biopsy is not needed if the patient has typical palpable purpura.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Direct histologic and immunochemical evidence of cryoglobulins from pathologic thrombotic or vasculitic specimens. While this direct demonstration of cryoglobulins may provide the most definitive evidence, it is rarely sought or performed in clinical practice or included in formal criteria. For example, tissue biopsies and histologic confirmation of the presence of cryoglobulins is not part of the classification criteria for cryoglobulinemic vasculitis proposed by the Italian Study Group on Cryoglobulinemia [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Occasionally, the clinician is faced with the diagnostic challenge of a patient with nonspecific symptoms, such as weakness or arthralgias in the presence of serum cryoglobulin. In such cases, evidence of a low C4 serum level or a frequently associated disorder, such as HCV infection or a clinically evident systemic disease (eg, Sjögren's disease) increases the likelihood of the presence of a clinically significant cryoglobulinemia syndrome.
        </p>
        <p class="headingAnchor" id="H40">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of cryoglobulinemia is broad and varies depending upon the clinical presentation, which can include signs and symptoms of cryoglobulinemic vasculitis or a hyperviscosity syndrome.
        </p>
        <p>
         The differential diagnosis of cryoglobulinemic vasculitis includes other vasculitides that affect small- or medium-sized vessels; these include drug-induced small vessel vasculitis (hypersensitivity vasculitis), IgA vasculitis (IgAV; Henoch-Schönlein purpura), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (eg, granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis [Churg-Strauss syndrome]), and infection-related vasculitis (eg, bacterial endocarditis, poststreptococcal vasculitis, and glomerulonephritis). Vasculitis associated with a connective tissue disorder (eg, systemic lupus erythematosus [SLE], rheumatoid arthritis, Sjögren's disease) may or may not be mediated by cryoglobulins. In addition, disorders that mimic the symptoms and findings of vasculitis, including infectious (eg, rickettsial infections, malaria, babesiosis), thrombotic, and embolic disorders (eg, antiphospholipid syndrome, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, atrial myxoma), may warrant consideration. Patients with chronic hepatitis C virus (HCV) infection may have membranoproliferative nephritis and arthralgias even in the absence of cryoglobulinemia, and these complications of HCV may overlap with findings of cryoglobulinemic vasculitis. The differential diagnosis of vasculitis is discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8226.html" rel="external">
          "Overview of and approach to the vasculitides in adults", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p>
         Slow flow and impaired tissue perfusion affecting many organs may be due to marked elevation of the cellular contents of the blood (eg, leukostasis, polycythemia), partial obstruction by sickled red blood cells, parasitized cells (eg, malaria, babesiosis), or increased viscosity due to polyclonal or monoclonal Igs that are not cryoglobulins (eg, Waldenström macroglobulinemia).
        </p>
        <p class="headingAnchor" id="H3491660470">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of cryoglobulinemia depends upon the underlying disorder and upon the severity and nature of involvement.
        </p>
        <p>
         In patients with symptomatic mixed cryoglobulinemia, the treatment is directed at the underlying infectious or autoimmune disorder, as well as the vasculitis that may occur. Treatment of mixed cryoglobulinemia is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3070.html" rel="external">
          "Mixed cryoglobulinemia syndrome: Treatment and prognosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6654.html" rel="external">
          "Treatment and prognosis of Waldenström macroglobulinemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3673.html" rel="external">
          "Overview of the management of chronic hepatitis C virus infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3642.html" rel="external">
          "Hepatitis B virus: Overview of management"
         </a>
         .)
        </p>
        <p>
         In patients with monoclonal (type I) cryoglobulin associated with a lymphoproliferative disorder, the treatment is focused on the underlying malignancy and the risk or presence of complications such as hyperviscosity syndrome. Some patients with hyperviscosity may require treatment with plasma exchange or other interventions. (See
         <a class="medical medical_review" href="/z/d/html/6654.html" rel="external">
          "Treatment and prognosis of Waldenström macroglobulinemia", section on 'Emergency management of hyperviscosity'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7941.html" rel="external">
          "Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology", section on 'Common uses of therapeutic apheresis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6643.html" rel="external">
          "Multiple myeloma: Overview of management", section on 'Other complications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1789088751">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prognosis generally relates to the underlying disease state(s) or developing complication(s), particularly in type I cryoglobulinemia, where the patient often suffers from a primary lymphoproliferative disorder [
         <a href="#rid48">
          48
         </a>
         ]. Patients with type II cryoglobulinemia are at increased risk to develop a B-cell non-Hodgkin lymphoma. Several studies have suggested that a handful of findings suggests poorer outcomes (ie, age, gastrointestinal or pulmonary involvement, renal insufficiency, four or more extrarenal manifestations, hypertension, and infectious complications [
         <a href="#rid2">
          2,52,98
         </a>
         ]), but little is known about the relative contributions of each. The presence of cryoglobulins per se does not seem to confer a significant morbidity or mortality risk over and above the underlying conditions.
        </p>
        <p class="headingAnchor" id="H44">
         <span class="h2">
          Survival
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mean survival is approximately 70 percent at 10 years after the onset of symptoms and 50 percent at 10 years after diagnosis, with death typically resulting from infection and cardiovascular disease. The prognosis for such patients depends upon their response to treatment (see
         <a class="medical medical_review" href="/z/d/html/3070.html" rel="external">
          "Mixed cryoglobulinemia syndrome: Treatment and prognosis"
         </a>
         ). Some complications of cryoglobulinemia predict poorer outcomes, including renal failure and development of a lymphoproliferative or plasma cell disorder.
        </p>
        <p>
         Hepatitis C virus (HCV)-associated cryoglobulinemic vasculitis is a severe disease with an estimated five-year mortality rate of 25 percent [
         <a href="#rid1">
          1,99
         </a>
         ]. Apart from liver fibrosis, the prognosis of HCV-associated cryoglobulinemic vasculitis is mainly dependent on vasculitic involvement of the kidney, central nervous system, heart, and gastrointestinal tract. However, more recent series report much lower mortality rates by using all oral interferon-free antiviral combinations with greater efficacy and better tolerance, and less use of immunosuppressants. (See
         <a class="medical medical_review" href="/z/d/html/3673.html" rel="external">
          "Overview of the management of chronic hepatitis C virus infection", section on 'Antiviral therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H45">
         <span class="h2">
          Renal failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of development of renal failure may be greater in those with hepatitis C-associated disease than in those with idiopathic (essential) mixed cryoglobulinemia. This was illustrated in one study of 17 patients, 11 of whom had hepatitis C infection; 5 of 11 of these patients developed renal failure, while none of the six patients free of infection had progressive renal disease [
         <a href="#rid89">
          89
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3065.html" rel="external">
          "Overview of kidney disease associated with hepatitis C virus infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H46">
         <span class="h2">
          Lymphoproliferative disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Secondary lymphoproliferative disorders sometimes occur, generally manifesting in type II patients 5 to 10 years after diagnosis, but do so in less than 5 to 10 percent of patients [
         <a href="#rid100">
          100-102
         </a>
         ]. The malignancy is often a B-cell non-Hodgkin lymphoma, approximately 50 percent intermediate-to-high-grade lymphoma and approximately 50 percent low-grade tumors such as immunocytoma (70 to 80 percent), mucosa-associated lymphoid tumors, or centrocytic follicular lymphoma.
        </p>
        <p>
         Among patients with hepatitis C-associated type II cryoglobulinemia, the incidence of non-Hodgkin lymphoma is estimated to be 35-fold higher than in the general population. The distribution of aggressive and nonaggressive histologic types is similar to that noted above for unselected patients with cryoglobulinemia. (See
         <a class="medical medical_review" href="/z/d/html/3676.html" rel="external">
          "Extrahepatic manifestations of hepatitis C virus infection", section on 'Lymphoma'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5780053">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Terminology
         </strong>
         – Cryoglobulins are immunoglobulins (Igs) in the serum that precipitate at temperatures below 37°C and redissolve on rewarming. Cryoglobulinemia refers to the presence of cryoglobulin in a patient's serum. This term is often used interchangeably with cryoglobulinemic vasculitis (or cryoglobulinemia syndrome). Cryoglobulinemic vasculitis (or cryoglobulinemia syndrome) refers to a systemic inflammatory syndrome that generally involves small-to-medium vessel vasculitis due to cryoglobulin-containing immune complexes. (See
         <a class="local">
          'Terminology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Classification
         </strong>
         – The Brouet classification criteria is the most commonly used system that classifies cryoglobulinemia into three different subgroups based on their Ig composition. These classification criteria are also useful in that the subgroups partly correlate with pathogenicity and clinical manifestations. (See
         <a class="local">
          'Classification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Type I
         </strong>
         – In type I cryoglobulinemia, the cryoglobulins are monoclonal Ig, typically IgG or IgM, and less commonly IgA or free Ig light chains. Type I cryoglobulinemia develops in the setting of protein-secreting monoclonal gammopathies such as a monoclonal gammopathy of undetermined significance (MGUS) or a B-cell lineage malignancy (eg, multiple myeloma, Waldenström macroglobulinemia, or chronic lymphocytic leukemia). (See
         <a class="local">
          'Type I'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Type II
         </strong>
         – In type II cryoglobulinemia, the cryoglobulins are composed of a mixture of a monoclonal IgM (or IgG or IgA) with rheumatoid factor (RF) activity and polyclonal Ig. Type II cryoglobulins are often associated with persistent viral infections, particularly hepatitis C virus (HCV) infection, and are associated with the mixed cryoglobulinemia syndrome. Other clinical associations with type II cryoglobulinemia include autoimmune diseases (mainly systemic lupus erythematosus [SLE] and Sjögren's disease), lymphoproliferative disorders, and other infections such as hepatitis B virus (HBV) and HIV. (See
         <a class="local">
          'Type II'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Type III
         </strong>
         – In type III cryoglobulinemia, the cryoglobulins are composed of a mixture of polyclonal IgG (all isotypes) and polyclonal IgM. These cases are often secondary to autoimmune disorders, but can also be associated with infections (mainly HCV). (See
         <a class="local">
          'Type III'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview of clinical presentation
         </strong>
         <strong>
          and disease associations
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Type I cryoglobulinemia
         </strong>
         – Type I cryoglobulinemia classically produces symptoms and signs related to vascular occlusion by the cryoprecipitate such as digital ischemia, livedo reticularis, skin necrosis, and purpura. Raynaud phenomenon and skin manifestations are commonly observed in these patients and are closely dependent on cold outside temperatures. When the cryocrit is high, symptoms of hyperviscosity may occur. (See
         <a class="local">
          'Mixed cryoglobulinemia (types II/III)'
         </a>
         above and
         <a class="local">
          'Specific clinical features'
         </a>
         above and
         <a class="local">
          'Overview of clinical presentation and disease associations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mixed cryoglobulinemia (types II/III)
         </strong>
         – Mixed cryoglobulinemia (types II/III) is most often associated with constitutional and nonspecific symptoms, such as arthralgias, fatigue, and myalgias, as well as palpable purpura due to cutaneous vasculitis and sensory changes or weakness due to peripheral neuropathy. Manifestations are not dependent on cold outside temperatures. The classical "Meltzer's triad" of purpura, arthralgias, and weakness is seen in most patients. (See
         <a class="local">
          'Mixed cryoglobulinemia (types II/III)'
         </a>
         above and
         <a class="local">
          'Specific clinical features'
         </a>
         above and
         <a class="local">
          'Overview of clinical presentation and disease associations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          When to suspect the diagnosis
         </strong>
         – The diagnosis of a cryoglobulinemia syndrome should be suspected in patients presenting with arthralgia, purpura, skin ulcers, glomerulonephritis, and peripheral neuropathy. The index of suspicion for cryoglobulinemia should be raised further if these occur in the setting of a clonal hematologic disease (eg, multiple myeloma, Waldenström macroglobulinemia, MGUS), viral infection (eg, HCV, HBV, HIV), or connective tissue disease (eg, SLE, Sjögren's disease) (see
         <a class="local">
          'When to suspect the diagnosis'
         </a>
         above). Diagnosis of a clinical disorder in association with cryoglobulin requires a careful consideration of combined clinical, laboratory, and pathologic data. The presence of a measurable amount of cryoglobulin (cryocrit) with a low C4 complement level remain the most prominent laboratory hallmarks of cryoglobulinemia syndromes. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – The diagnostic evaluation for a case of possible cryoglobulinemic vasculitis should include a detailed history including infectious disease exposure (eg, hepatitis B or C virus, HIV), a prior history of a clonal hematologic disease (eg, multiple myeloma, Waldenström macroglobulinemia, MGUS) or systemic autoimmune disease (especially SLE or Sjögren's disease), and symptoms or manifestations that may characterize or exclude a suspected diagnosis; a careful physical examination; laboratory testing to include detection of cryoglobulins, serum chemistries, urinalysis, complement (especially C4 level), RF, viral serologies (particularly for HBV, HCV, and HIV), acute phase reactants, as well as other autoantibodies such as antinuclear antibodies (ANAs) and antineutrophil cytoplasmic antibody (ANCA). (See
         <a class="local">
          'Evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – The treatment of cryoglobulinemia depends upon the underlying disorder and upon the severity and nature of involvement. In patients with mixed cryoglobulinemia (type II or III), the treatment is directed at the underlying infectious or autoimmune disorder, as well as the vasculitis that may occur. In patients with monoclonal (type I) cryoglobulin associated with a lymphoproliferative disorder, the treatment is focused on the underlying malignancy and the risk or presence of complications such as hyperviscosity syndrome. Some patients with hyperviscosity may require treatment with plasma exchange or other interventions. (See
         <a class="medical medical_review" href="/z/d/html/3070.html" rel="external">
          "Mixed cryoglobulinemia syndrome: Treatment and prognosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6654.html" rel="external">
          "Treatment and prognosis of Waldenström macroglobulinemia", section on 'Emergency management of hyperviscosity'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7941.html" rel="external">
          "Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology", section on 'Common uses of therapeutic apheresis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6643.html" rel="external">
          "Multiple myeloma: Overview of management", section on 'Other complications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Prognosis generally relates to the underlying disease state(s) or developing complication(s), particularly in type I cryoglobulinemia, where the patient often suffers from a primary lymphoproliferative disorder. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H70327158">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Stanford L Peng, MD, PhD, and Peter H Schur, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Ramos-Casals M, Stone JH, Cid MC, Bosch X. The cryoglobulinaemias. Lancet 2012; 379:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brouet JC, Clauvel JP, Danon F, et al. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974; 57:775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trejo O, Ramos-Casals M, García-Carrasco M, et al. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore) 2001; 80:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musset L, Diemert MC, Taibi F, et al. Characterization of cryoglobulins by immunoblotting. Clin Chem 1992; 38:798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tissot JD, Schifferli JA, Hochstrasser DF, et al. Two-dimensional polyacrylamide gel electrophoresis analysis of cryoglobulins and identification of an IgM-associated peptide. J Immunol Methods 1994; 173:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pascual M, Perrin L, Giostra E, Schifferli JA. Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis 1990; 162:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musset L, Duarte F, Gaillard O, et al. Immunochemical characterization of monoclonal IgG containing mixed cryoglobulins. Clin Immunol Immunopathol 1994; 70:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyle RA, Rajkumar SV. Monoclonal gammopathies of undetermined significance. Hematol Oncol Clin North Am 1999; 13:1181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monti G, Galli M, Invernizzi F, et al. Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM 1995; 88:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonnet F, Pineau JJ, Taupin JL, et al. Prevalence of cryoglobulinemia and serological markers of autoimmunity in human immunodeficiency virus infected individuals: a cross-sectional study of 97 patients. J Rheumatol 2003; 30:2005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García-Carrasco M, Ramos-Casals M, Cervera R, et al. Cryoglobulinemia in systemic lupus erythematosus: prevalence and clinical characteristics in a series of 122 patients. Semin Arthritis Rheum 2001; 30:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-Casals M, Cervera R, Yagüe J, et al. Cryoglobulinemia in primary Sjögren's syndrome: prevalence and clinical characteristics in a series of 115 patients. Semin Arthritis Rheum 1998; 28:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cicardi M, Cesana B, Del Ninno E, et al. Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C. J Viral Hepat 2000; 7:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-Casals M, Muñoz S, Medina F, et al. Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol 2009; 36:1442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montagnino G. Reappraisal of the clinical expression of mixed cryoglobulinemia. Springer Semin Immunopathol 1988; 10:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-Casals M, Trejo O, García-Carrasco M, et al. Mixed cryoglobulinemia: new concepts. Lupus 2000; 9:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zignego AL, Wojcik GL, Cacoub P, et al. Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. Genes Immun 2014; 15:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antonelli A, Ferri C, Ferrari SM, et al. Serum levels of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor alpha in mixed cryoglobulinemia. Arthritis Rheum 2009; 60:3841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fabris P, Tositti G, Giordani MT, et al. Prevalence and clinical significance of circulating cryoglobulins in HIV-positive patients with and without co-infection with hepatitis C virus. J Med Virol 2003; 69:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belizna CC, Hamidou MA, Levesque H, et al. Infection and vasculitis. Rheumatology (Oxford) 2009; 48:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng YC, Schifferli JA. Clearance of cryoglobulins in man. Springer Semin Immunopathol 1988; 10:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fornasieri A, Li M, Armelloni S, et al. Glomerulonephritis induced by human IgMK-IgG cryoglobulins in mice. Lab Invest 1993; 69:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grey HM, Kohler PF. Cryoimmunoglobulins. Semin Hematol 1973; 10:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boleto G, Ghillani-Dalbin P, Musset L, et al. Cryoglobulinemia after the era of chronic hepatitis C infection. Semin Arthritis Rheum 2020; 50:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cacoub P, Saadoun D. Extrahepatic Manifestations of Chronic HCV Infection. N Engl J Med 2021; 384:1038.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferraccioli GF, De Vita S, Casatta L, et al. Autoimmune connective tissue disease, chronic polyarthritides and B cell expansion: risks and perspectives with immunosuppressive drugs. Clin Exp Rheumatol 1996; 14 Suppl 14:S71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Re V, De Vita S, Sansonno D, et al. Type II mixed cryoglobulinaemia as an oligo rather than a mono B-cell disorder: evidence from GeneScan and MALDI-TOF analyses. Rheumatology (Oxford) 2006; 45:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998; 282:938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327:1490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agnello V. The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection. Springer Semin Immunopathol 1997; 19:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charles ED, Green RM, Marukian S, et al. Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood 2008; 111:1344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charles ED, Brunetti C, Marukian S, et al. Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood 2011; 117:5425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knight GB, Gao L, Gragnani L, et al. Detection of WA B cells in hepatitis C virus infection: a potential prognostic marker for cryoglobulinemic vasculitis and B cell malignancies. Arthritis Rheum 2010; 62:2152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schott P, Polzien F, Müller-Issberner A, et al. In vitro reactivity of cryoglobulin IgM and IgG in hepatitis C virus-associated mixed cryoglobulinemia. J Hepatol 1998; 28:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyer O, Saadoun D, Abriol J, et al. CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood 2004; 103:3428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landau DA, Rosenzwajg M, Saadoun D, et al. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis. Arthritis Rheum 2008; 58:2897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011; 365:2067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kunkel HG, Winchester RJ, Joslin FG, Capra JD. Similarities in the light chains of anti-gamma-globulins showing cross-idiotypic specificities. J Exp Med 1974; 139:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zinneman HH. Cryoglobulins and pyroglobulins. Pathobiol Annu 1980; 10:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saha A, Chowdhury P, Sambury S, et al. Studies on cryoprecipitation. IV. Enzymic fragments of a human cryoglobulin. J Biol Chem 1970; 245:2730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haakenstad AO, Mannik M. Saturation of the reticuloendothelial system with soluble immune complexes. J Immunol 1974; 112:1939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamburger MI, Gorevic PD, Lawley TJ, et al. Mixed cryoglobulinemia: association of glomerulonephritis with defective reticuloendothelial system Fc receptor function. Trans Assoc Am Physicians 1979; 92:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berliner S, Weinberger A, Zamir R, et al. Familial cryoglobulinemia and C4 deficiency. Scand J Rheumatol 1984; 13:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McLean RH, Weinstein A, Chapitis J, et al. Familial partial deficiency of the third component of complement (C3) and the hypocomplementemic cutaneous vasculitis syndrome. Am J Med 1980; 68:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terrier B, Karras A, Kahn JE, et al. The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases. Medicine (Baltimore) 2013; 92:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harel S, Mohr M, Jahn I, et al. Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases. Br J Haematol 2015; 168:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muchtar E, Magen H, Gertz MA. How I treat cryoglobulinemia. Blood 2017; 129:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sidana S, Rajkumar SV, Dispenzieri A, et al. Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. Am J Hematol 2017; 92:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Della Rossa A, Trevisani G, Bombardieri S. Cryoglobulins and cryoglobulinemia. Diagnostic and therapeutic considerations. Clin Rev Allergy Immunol 1998; 16:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meltzer M, Franklin EC. Cryoglobulinemia--a study of twenty-nine patients. I. IgG and IgM cryoglobulins and factors affecting cryoprecipitability. Am J Med 1966; 40:828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dispenzieri A, Gorevic PD. Cryoglobulinemia. Hematol Oncol Clin North Am 1999; 13:1315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorevic PD, Kassab HJ, Levo Y, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980; 69:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen SJ, Pittelkow MR, Su WP. Cutaneous manifestations of cryoglobulinemia: clinical and histopathologic study of seventy-two patients. J Am Acad Dermatol 1991; 25:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giuggioli D, Manfredi A, Lumetti F, et al. Cryoglobulinemic vasculitis and skin ulcers. Our therapeutic strategy and review of the literature. Semin Arthritis Rheum 2015; 44:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossi D, Mansouri M, Baldovino S, et al. Nail fold videocapillaroscopy in mixed cryoglobulinaemia. Nephrol Dial Transplant 2004; 19:2245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinberger A, Berliner S, Pinkhas J. Articular manifestations of essential cryoglobulinemia. Semin Arthritis Rheum 1981; 10:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferri C, La Civita L, Cirafisi C, et al. Peripheral neuropathy in mixed cryoglobulinemia: clinical and electrophysiologic investigations. J Rheumatol 1992; 19:889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gemignani F, Pavesi G, Fiocchi A, et al. Peripheral neuropathy in essential mixed cryoglobulinaemia. J Neurol Neurosurg Psychiatry 1992; 55:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gemignani F, Melli G, Inglese C, Marbini A. Cryoglobulinemia is a frequent cause of peripheral neuropathy in undiagnosed referral patients. J Peripher Nerv Syst 2002; 7:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Bragado F, Fernandez JM, Navarro C, et al. Peripheral neuropathy in essential mixed cryoglobulinemia. Arch Neurol 1988; 45:1210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stricker RB, Sanders KA, Owen WF, et al. Mononeuritis multiplex associated with cryoglobulinemia in HIV infection. Neurology 1992; 42:2103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stricker RB, Kiprov DD. Mononeuritis and cryoglobulins. Neurology 1993; 43:2159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levo Y, Gorevic PD, Kassab HJ, et al. Association between hepatitis B virus and essential mixed cryoglobulinemia. N Engl J Med 1977; 296:1501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schena FP. Survey of the Italian Registry of Renal Biopsies. Frequency of the renal diseases for 7 consecutive years. The Italian Group of Renal Immunopathology. Nephrol Dial Transplant 1997; 12:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaidan M, Terrier B, Pozdzik A, et al. Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN. J Am Soc Nephrol 2016; 27:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matignon M, Cacoub P, Colombat M, et al. Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection. Medicine (Baltimore) 2009; 88:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bombardieri S, Paoletti P, Ferri C, et al. Lung involvement in essential mixed cryoglobulinemia. Am J Med 1979; 66:748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viegi G, Fornai E, Ferri C, et al. Lung function in essential mixed cryoglobulinemia: a short-term follow-up. Clin Rheumatol 1989; 8:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bertorelli G, Pesci A, Manganelli P, et al. Subclinical pulmonary involvement in essential mixed cryoglobulinemia assessed by bronchoalveolar lavage. Chest 1991; 100:1478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarantino A, De Vecchi A, Montagnino G, et al. Renal disease in essential mixed cryoglobulinaemia. Long-term follow-up of 44 patients. Q J Med 1981; 50:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vermeersch P, Gijbels K, Mariën G, et al. A critical appraisal of current practice in the detection, analysis, and reporting of cryoglobulins. Clin Chem 2008; 54:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trendelenburg M, Schifferli JA. Cryoglobulins are not essential. Ann Rheum Dis 1998; 57:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Della Rossa A, Tavoni A, D'Ascanio A, et al. Mortality rate and outcome factors in mixed cryoglobulinaemia: the impact of hepatitis C virus. Scand J Rheumatol 2010; 39:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sene D, Ghillani-Dalbin P, Thibault V, et al. Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus. J Rheumatol 2004; 31:2199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kay J, McCluskey RT. Case records of the Massachusetts General Hospital. Case 31-2005. A 60-year-old man with skin lesions and renal insufficiency. N Engl J Med 2005; 353:1605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarantino A, Anelli A, Costantino A, et al. Serum complement pattern in essential mixed cryoglobulinaemia. Clin Exp Immunol 1978; 32:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hebert LA, Cosio FG, Neff JC. Diagnostic significance of hypocomplementemia. Kidney Int 1991; 39:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Misiani R, Bellavita P, Fenili D, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992; 117:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levo Y. Hepatitis B virus and essential mixed cryoglobulinemia. Ann Intern Med 1981; 94:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Popp JW Jr, Dienstag JL, Wands JR, Bloch KJ. Essential mixed cryoglobulinemia without evidence for hepatitis B virus infection. Ann Intern Med 1980; 92:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wener MH, Hutchinson K, Morishima C, Gretch DR. Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia. Arthritis Rheum 2004; 50:2305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen P, Nguyen QT, Dény P, et al. Treatment of mixed cryoglobulinemia with recombinant interferon alpha and adjuvant therapies. A prospective study on 20 patients. Ann Med Interne (Paris) 1996; 147:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chad D, Pariser K, Bradley WG, et al. The pathogenesis of cryoglobulinemic neuropathy. Neurology 1982; 32:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nemni R, Corbo M, Fazio R, et al. Cryoglobulinaemic neuropathy. A clinical, morphological and immunocytochemical study of 8 cases. Brain 1988; 111 ( Pt 3):541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tredici G, Petruccioli MG, Cavaletti G, et al. Sural nerve bioptic findings in essential cryoglobulinemic patients with and without peripheral neuropathy. Clin Neuropathol 1992; 11:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonetti B, Invernizzi F, Rizzuto N, et al. T-cell-mediated epineurial vasculitis and humoral-mediated microangiopathy in cryoglobulinemic neuropathy. J Neuroimmunol 1997; 73:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cavaletti G, Petruccioli MG, Crespi V, et al. A clinico-pathological and follow up study of 10 cases of essential type II cryoglobulinaemic neuropathy. J Neurol Neurosurg Psychiatry 1990; 53:886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saadoun D, Terrier B, Semoun O, et al. Hepatitis C virus-associated polyarteritis nodosa. Arthritis Care Res (Hoboken) 2011; 63:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beddhu S, Bastacky S, Johnson JP. The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine (Baltimore) 2002; 81:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dammacco F, Sansonno D. Mixed cryoglobulinemia as a model of systemic vasculitis. Clin Rev Allergy Immunol 1997; 15:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karras A, Noël LH, Droz D, et al. Renal involvement in monoclonal (type I) cryoglobulinemia: two cases associated with IgG3 kappa cryoglobulin. Am J Kidney Dis 2002; 40:1091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Su CF, Chen HH, Yeh JC, et al. Ultrastructural 'fingerprint' in cryoprecipitates and glomerular deposits: a clinicopathologic analysis of fingerprint deposits. Nephron 2002; 90:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monteverde A, Ballarè M, Bertoncelli MC, et al. Lymphoproliferation in type II mixed cryoglobulinemia. Clin Exp Rheumatol 1995; 13 Suppl 13:S141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zignego AL, Giannelli F, Marrocchi ME, et al. Frequency of bcl-2 rearrangement in patients with mixed cryoglobulinemia and HCV-positive liver diseases. Clin Exp Rheumatol 1997; 15:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quartuccio L, Isola M, Corazza L, et al. Validation of the classification criteria for cryoglobulinaemic vasculitis. Rheumatology (Oxford) 2014; 53:2209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Invernizzi F, Pietrogrande M, Sagramoso B. Classification of the cryoglobulinemic syndrome. Clin Exp Rheumatol 1995; 13 Suppl 13:S123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terrier B, Carrat F, Krastinova E, et al. Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey. Ann Rheum Dis 2013; 72:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cacoub P, Comarmond C, Domont F, et al. Cryoglobulinemia Vasculitis. Am J Med 2015; 128:950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Invernizzi F, Pioltelli P, Cattaneo R, et al. A long-term follow-up study in essential cryoglobulinemia. Acta Haematol 1979; 61:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           La Civita L, Zignego AL, Monti M, et al. Mixed cryoglobulinemia as a possible preneoplastic disorder. Arthritis Rheum 1995; 38:1859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saadoun D, Sellam J, Ghillani-Dalbin P, et al. Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med 2006; 166:2101.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1825 Version 36.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21868085" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The cryoglobulinaemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4216269" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Biologic and clinical significance of cryoglobulins. A report of 86 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11470986" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1597004" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Characterization of cryoglobulins by immunoblotting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8034987" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Two-dimensional polyacrylamide gel electrophoresis analysis of cryoglobulins and identification of an IgM-associated peptide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2115556" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Hepatitis C virus in patients with cryoglobulinemia type II.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8299232" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Immunochemical characterization of monoclonal IgG containing mixed cryoglobulins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10626144" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Monoclonal gammopathies of undetermined significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7704562" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12966606" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Prevalence of cryoglobulinemia and serological markers of autoimmunity in human immunodeficiency virus infected individuals: a cross-sectional study of 97 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11303309" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Cryoglobulinemia in systemic lupus erythematosus: prevalence and clinical characteristics in a series of 122 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9872481" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Cryoglobulinemia in primary Sjögren's syndrome: prevalence and clinical characteristics in a series of 115 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10760044" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19369460" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3046019" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Reappraisal of the clinical expression of mixed cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10787003" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mixed cryoglobulinemia: new concepts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25030430" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19950277" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Serum levels of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor alpha in mixed cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12526043" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Prevalence and clinical significance of circulating cryoglobulins in HIV-positive patients with and without co-infection with hepatitis C virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19258377" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Infection and vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2970686" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Clearance of cryoglobulins in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8246445" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Glomerulonephritis induced by human IgMK-IgG cryoglobulins in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4633223" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Cryoimmunoglobulins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32521323" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Cryoglobulinemia after the era of chronic hepatitis C infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33730456" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Extrahepatic Manifestations of Chronic HCV Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8722204" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Autoimmune connective tissue disease, chronic polyarthritides and B cell expansion: risks and perspectives with immunosuppressive drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16399842" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Type II mixed cryoglobulinaemia as an oligo rather than a mono B-cell disorder: evidence from GeneScan and MALDI-TOF analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9794763" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Binding of hepatitis C virus to CD81.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1383822" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : A role for hepatitis C virus infection in type II cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9266635" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17942751" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21421840" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20506150" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Detection of WA B cells in hepatitis C virus infection: a potential prognostic marker for cryoglobulinemic vasculitis and B cell malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9537859" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : In vitro reactivity of cryoglobulin IgM and IgG in hepatitis C virus-associated mixed cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14684420" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18759287" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22129253" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4543460" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Similarities in the light chains of anti-gamma-globulins showing cross-idiotypic specificities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7003499" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Cryoglobulins and pyroglobulins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4192284" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Studies on cryoprecipitation. IV. Enzymic fragments of a human cryoglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4818464" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Saturation of the reticuloendothelial system with soluble immune complexes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/549248" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Mixed cryoglobulinemia: association of glomerulonephritis with defective reticuloendothelial system Fc receptor function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6740270" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Familial cryoglobulinemia and C4 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7369233" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Familial partial deficiency of the third component of complement (C3) and the hypocomplementemic cutaneous vasculitis syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23429354" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25363150" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27799164" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : How I treat cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28370486" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9773252" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Cryoglobulins and cryoglobulinemia. Diagnostic and therapeutic considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4956870" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Cryoglobulinemia--a study of twenty-nine patients. I. IgG and IgM cryoglobulins and factors affecting cryoprecipitability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10626153" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6996482" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1880249" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Cutaneous manifestations of cryoglobulinemia: clinical and histopathologic study of seventy-two patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25547031" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Cryoglobulinemic vasculitis and skin ulcers. Our therapeutic strategy and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15238627" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Nail fold videocapillaroscopy in mixed cryoglobulinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7233245" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Articular manifestations of essential cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1328632" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Peripheral neuropathy in mixed cryoglobulinemia: clinical and electrophysiologic investigations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1311372" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Peripheral neuropathy in essential mixed cryoglobulinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11939353" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Cryoglobulinemia is a frequent cause of peripheral neuropathy in undiagnosed referral patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2847694" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Peripheral neuropathy in essential mixed cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1436518" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Mononeuritis multiplex associated with cryoglobulinemia in HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8414001" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Mononeuritis and cryoglobulins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/865530" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Association between hepatitis B virus and essential mixed cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9075118" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Survey of the Italian Registry of Renal Biopsies. Frequency of the renal diseases for 7 consecutive years. The Italian Group of Renal Immunopathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26260165" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19910748" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/443251" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Lung involvement in essential mixed cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2805608" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Lung function in essential mixed cryoglobulinemia: a short-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1935328" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Subclinical pulmonary involvement in essential mixed cryoglobulinemia assessed by bronchoalveolar lavage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7267965" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Renal disease in essential mixed cryoglobulinaemia. Long-term follow-up of 44 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17998269" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : A critical appraisal of current practice in the detection, analysis, and reporting of cryoglobulins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9536813" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Cryoglobulins are not essential.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20337547" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Mortality rate and outcome factors in mixed cryoglobulinaemia: the impact of hepatitis C virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15517633" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16221784" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Case records of the Massachusetts General Hospital. Case 31-2005. A 60-year-old man with skin lesions and renal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/668194" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Serum complement pattern in essential mixed cryoglobulinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1829775" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Diagnostic significance of hypocomplementemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1326246" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Hepatitis C virus infection in patients with essential mixed cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7469231" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Hepatitis B virus and essential mixed cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7356231" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Essential mixed cryoglobulinemia without evidence for hepatitis B virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15248231" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8760684" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Treatment of mixed cryoglobulinemia with recombinant interferon alpha and adjuvant therapies. A prospective study on 20 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6283424" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The pathogenesis of cryoglobulinemic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2838123" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Cryoglobulinaemic neuropathy. A clinical, morphological and immunocytochemical study of 8 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1319290" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Sural nerve bioptic findings in essential cryoglobulinemic patients with and without peripheral neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9058770" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : T-cell-mediated epineurial vasculitis and humoral-mediated microangiopathy in cryoglobulinemic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2176233" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : A clinico-pathological and follow up study of 10 cases of essential type II cryoglobulinaemic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20981809" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Hepatitis C virus-associated polyarteritis nodosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12352634" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : The clinical and morphologic spectrum of renal cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9209804" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Mixed cryoglobulinemia as a model of systemic vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7723249" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12407656" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Renal involvement in monoclonal (type I) cryoglobulinemia: two cases associated with IgG3 kappa cryoglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11744803" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Ultrastructural 'fingerprint' in cryoprecipitates and glomerular deposits: a clinicopathologic analysis of fingerprint deposits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8730495" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Lymphoproliferation in type II mixed cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9444437" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Frequency of bcl-2 rearrangement in patients with mixed cryoglobulinemia and HCV-positive liver diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24994905" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Validation of the classification criteria for cryoglobulinaemic vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8730492" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Classification of the cryoglobulinemic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22586172" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25837517" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Cryoglobulinemia Vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/105549" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : A long-term follow-up study in essential cryoglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8849361" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Mixed cryoglobulinemia as a possible preneoplastic disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17060540" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
